Participants were included in the Classification in Axial Spondyloarthritis Inception Cohort Study (CLASSIC) if they were referred to a rheumatologist with undiagnosed chronic back pain occurring before 45 years of age, with ≥3 months' duration, and with suspicion of axial spondyloarthritis [2]. Global assessments were conducted to validate the criteria using clinical assessment, laboratory analyses, pelvic radiographs, local MRI, and a centralised review of imaging data. A prespecified sensitivity of ≥75% and specificity of ≥90% was used to select diagnostic criteria. A total of 1,015 participants from 61 centres in 27 countries were included.
Following central review of data, 36.4% of participants in the cohort were diagnosed with axial spondyloarthritis. Several diagnostic models were proposed based on imaging, genetic, and clinical criteria. The model reaching the highest specificity (sensitivity of 79.5% and specificity of 90.4% for local readers) was based on a score ≥11, calculated as the sum of the following:
- MRI indicating axial spondyloarthritis (8) or radiographic sacroiliitis (7)
- HLA-B27 positivity (4)
- Inflammatory back pain (3)
- Peripheral arthritis (1)
- Inflammatory bowel disease (1)
- Acute anterior uveitis (1)
- Heel enthesitis (1)
- Elevated C-reactive protein (1)
- Psoriasis (1)
The adoption of these revised criteria was voted on by joint ASAS-SPARTAN members and was accepted by 158 votes in favour, 151 against, and 9 abstentions.
- Maksymowych WP, et al. Ann Rheum Dis. 2009;68(6):777-83.
- Maksymowych WP, et al. The assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) revised classification criteria for axial spondyloarthritis: Development and validation in the Classification in Axial SpA Inception Cohort Study. ACR Convergence, 24–29 October 2025, Chicago, IL, USA.
Medical writing support was provided by Mihai Surducan, PhD.
Copyright ©2025 Medicom Publishing Group
Posted on
Previous Article
« LEVI-04 holds potential to be the first disease-modifying therapy for knee osteoarthritis Next Article
Phase 2b data show that rosnilimab is effective in rheumatoid arthritis »
« LEVI-04 holds potential to be the first disease-modifying therapy for knee osteoarthritis Next Article
Phase 2b data show that rosnilimab is effective in rheumatoid arthritis »
Table of Contents: ACR 2025
Featured articles
Head-to-head trial shows secukinumab superior to ustekinumab in psoriatic arthritis
Phase 3 data reinforce ianalumab activity in Sjögren’s disease
A joint ASAS/SPARTAN initiative proposes revised diagnostic criteria for axial spondyloarthritis
Online First
Many high-risk post-menopausal women in the USA remain undertreated for osteoporosis
IDH1/2 mutations linked to inflammatory and rheumatological disorders
NTR-441 is an emerging treatment option for rheumatological conditions
Hydroxychloroquine blood level monitoring may reduce toxicity risk in lupus
Head-to-head trial shows secukinumab superior to ustekinumab in psoriatic arthritis
Telitacicept reveals positive efficacy data in Chinese patients with Sjögren’s disease
CAR Treg cells show initial efficacy in hard-to-treat rheumatoid arthritis
Phase 3 data reinforce ianalumab activity in Sjögren’s disease
Deucravacitinib holds promise for patients with psoriatic arthritis
Phase 2b data show that rosnilimab is effective in rheumatoid arthritis
A joint ASAS/SPARTAN initiative proposes revised diagnostic criteria for axial spondyloarthritis
LEVI-04 holds potential to be the first disease-modifying therapy for knee osteoarthritis
A urinary tenascin-C biomarker score predicts long-term kidney function in lupus nephritis
GLP-1 receptor agonists may protect against cardiac events in patients with psoriatic arthritis
Two-year treatment with upadacitinib shows high remission in patients with giant cell arteritis
Related Articles
June 30, 2025
EULAR 2025 Highlights Podcast
June 18, 2025
Inhibition of TLR7 and 8: A new way to treat lupus?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
